Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmAthene and Medarex have announced that the US Department of Defense appropriations bill for 2008 includes $0.8 million payable to PharmAthene on a cost reimbursement basis to support ongoing development of Valortim, which is being developed for the treatment of anthrax.
Subscribe to our email newsletter
This is the third consecutive year in which PharmAthene has received appropriations funding for Valortim, a fully human monoclonal antibody generated by Medarex’s UltiMAb technology that is being co-developed by the two companies.
Matthew Meldorf, senior program director for Valortim at PharmAthene, said: “The latest Department of Defense appropriations funding will be used to support further study of Valortim in a promising new animal model of anthrax infection.
“The new model, which is being developed at the US Army Medical Research Institute of Infectious Disease, seeks to improve on existing therapeutic models for anthrax by closely monitoring the disease process to establish the presence of anthrax bacteremia and to determine the optimal window for therapeutic intervention.”